Am. J. Respir. Crit. Care Med., Volume 159, Number 1, January 1999, 220-227

Lovastatin Induces Fibroblast Apoptosis In Vitro and In Vivo
A Possible Therapy for Fibroproliferative Disorders

ANNIE TAN, HÉLÈNE LEVREY, CORNELIA DAHM, VITALY A. POLUNOVSKY, JEFFREY RUBINS, and PETER B. BITTERMAN

Department of Medicine, Pulmonary, Allergy and Critical Care Division, and Department of Internal Medicine, University of Minnesota Medical School; and Veterans Affairs Medical Center, Minneapolis, Minnesota

Diseases associated with pathological fibroproliferation represent a major cause of morbidity and mortality. Despite the importance of this class of disorders, current therapy is of limited value, and no therapy is available to reduce the fibroblast population size within existing fibrotic lesions. In this regard, constitutive expression of growth-promoting genes can sensitize cells to undergo apoptosis. Studies in our laboratory have demonstrated that lovastatin potently induces apoptosis in fibroblasts constitutively expressing Myc, and that lung fibroblasts isolated from fibrotic lesions constitutively express growth-promoting genes. In this study, we sought to determine if nontransformed lung fibroblasts would manifest susceptibility to lovastatin-induced apoptosis similar to that observed in fibroblasts ectopically expressing Myc. Here we show that clinically achievable concentrations of lovastatin induce apoptosis in normal and fibrotic lung fibroblasts in vitro, as evidenced by acridine orange staining, terminal transferase nick end translation (TUNEL), and DNA laddering. Apoptosis of human lung fibroblasts was dose- and time-dependent, and blocked by exogenous mevalonic acid. Furthermore, apoptosis was associated with decreased levels of mature Ras, a molecule directly implicated in fibroblast rescue from apoptosis. The ability of lovastatin to induce fibroblast apoptosis in vivo was examined using a guinea pig wound chamber model. Lovastatin (5 µM, 8 d) reduced granulation tissue formation in the wound chambers by 64.7%, with associated ultrastructural evidence of fibroblast apoptosis. These findings support further study of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors as potential therapy for patients with fibroproliferative disorders.

This article has been cited by other articles:

				J. Reis, Xiaoyu Tan, Rongjie Yang, C. E. Rockwell, C. J. Papasian, S. N. Vogel, D. C. Morrison, A. A. Qureshi, and N. Qureshi A combination of proteasome inhibitors and antibiotics prevents lethality in a septic shock model Innate Immunity, October 1, 2008; 14(5): 319 - 329. [Abstract] [PDF]

				A. B. Fernandez, R. H. Karas, A. A. Alsheikh-Ali, and P. D. Thompson Statins and Interstitial Lung Disease: A Systematic Review of the Literature and of Food and Drug Administration Adverse Event Reports Chest, October 1, 2008; 134(4): 824 - 830. [Abstract] [Full Text] [PDF]

				J. I. Keddissi, W. G. Younis, E. A. Chbeir, N. N. Daher, T. A. Dernaika, and G. T. Kinasewitz The Use of Statins and Lung Function in Current and Former Smokers Chest, December 1, 2007; 132(6): 1764 - 1771. [Abstract] [Full Text] [PDF]

				Y. Kabuyama, K. Oshima, T. Kitamura, M. Homma, J. Yamaki, M. Munakata, and Y. Homma Involvement of selenoprotein P in the regulation of redox balance and myofibroblast viability in idiopathic pulmonary fibrosis. Genes Cells, November 1, 2007; 12(11): 1235 - 1244. [Abstract] [Full Text] [PDF]

				J. L. Gardner, S. M. Turner, A. Bautista, G. Lindwall, M. Awada, and M. K. Hellerstein Measurement of liver collagen synthesis by heavy water labeling: effects of profibrotic toxicants and antifibrotic interventions Am J Physiol Gastrointest Liver Physiol, June 1, 2007; 292(6): G1695 - G1705. [Abstract] [Full Text] [PDF]

				N. Walter, H. R. Collard, and T. E. King Jr. Current perspectives on the treatment of idiopathic pulmonary fibrosis. Proceedings of the ATS, January 1, 2006; 3(4): 330 - 338. [Abstract] [Full Text] [PDF]

				V. J. Thannickal and J. C. Horowitz Evolving concepts of apoptosis in idiopathic pulmonary fibrosis. Proceedings of the ATS, January 1, 2006; 3(4): 350 - 356. [Abstract] [Full Text] [PDF]

				K. L. Watts, E. M. Sampson, G. S. Schultz, and M. A. Spiteri Simvastatin Inhibits Growth Factor Expression and Modulates Profibrogenic Markers in Lung Fibroblasts Am. J. Respir. Cell Mol. Biol., April 1, 2005; 32(4): 290 - 300. [Abstract] [Full Text] [PDF]

				H. F. Nadrous, J. H. Ryu, W. W. Douglas, P. A. Decker, and E. J. Olson Impact of Angiotensin-Converting Enzyme Inhibitors and Statins on Survival in Idiopathic Pulmonary Fibrosis Chest, August 1, 2004; 126(2): 438 - 446. [Abstract] [Full Text] [PDF]

				N. Kaminski, J. A. Belperio, P. B. Bitterman, L. Chen, S. W. Chensue, A. M.K. Choi, S. Dacic, J. H. Dauber, R. M. du Bois, J. J. Enghild, et al. Idiopathic Pulmonary Fibrosis Am. J. Respir. Cell Mol. Biol., September 1, 2003; 29(3): S1 - 105. [Full Text] [PDF]

				T. Ishii, T. Matsuse, H. Igarashi, M. Masuda, S. Teramoto, and Y. Ouchi Tobacco smoke reduces viability in human lung fibroblasts: protective effect of glutathione S-transferase P1 Am J Physiol Lung Cell Mol Physiol, June 1, 2001; 280(6): L1189 - L1195. [Abstract] [Full Text] [PDF]

				M. Selman, T. E. King Jr., and A. Pardo Idiopathic Pulmonary Fibrosis: Prevailing and Evolving Hypotheses about Its Pathogenesis and Implications for Therapy Ann Intern Med, January 16, 2001; 134(2): 136 - 151. [Abstract] [Full Text] [PDF]

				H. Ando, T. Takamura, T. Ota, Y. Nagai, and K.-i. Kobayashi Cerivastatin Improves Survival of Mice with Lipopolysaccharide-Induced Sepsis J. Pharmacol. Exp. Ther., September 1, 2000; 294(3): 1043 - 1046. [Abstract] [Full Text]

				W. W. DOUGLAS, J. H. RYU, and D. R. SCHROEDER Idiopathic Pulmonary Fibrosis . Impact of Oxygen and Colchicine, Prednisone, or No Therapy on Survival Am. J. Respir. Crit. Care Med., April 1, 2000; 161(4): 1172 - 1178. [Abstract] [Full Text]

				N. NASREEN, K. A. MOHAMMED, P. A. DOWLING, M. J. WARD, G. GALFFY, and V. B. ANTONY Talc Induces Apoptosis in Human Malignant Mesothelioma Cells In Vitro Am. J. Respir. Crit. Care Med., February 1, 2000; 161(2): 595 - 600. [Abstract] [Full Text]

				A. Faggiotto and R. Paoletti Statins and Blockers of the Renin-Angiotensin System : Vascular Protection Beyond Their Primary Mode of Action Hypertension, October 1, 1999; 34(4): 987 - 996. [Abstract] [Full Text] [PDF]